Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections, including COVID-19. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton.
SNG001 is a host-directed, broad-spectrum antiviral that directly targets the site of infection - the lungs. Its mode of action does not depend on a particular virus or variant.
Data from our trials and subsequent analyses supports the potential of SNG001 to provide clinically important benefits in the treatment of severe viral lung infections. Synairgen now has data from its Phase 3 SPRINTER trial in patients hospitalised with COVID-19, subsequent analyses of different high-risk patient groups within the trial, the 60- and 90-day follow-up Long COVID data, as well as the data from the COPD trial conducted before the pandemic. The SPRINTER data were well-received at two major respiratory congresses: the ATS International Conference in San Francisco in May 2022 and the ERS International Congress in September 2022 and have been accepted for presentation at IDWeek in October 2022 in Washington, DC.
With input from clinical advisers, a review of data across our clinical development programmes further supports our approach to investigate SNG001 as a broad-spectrum antiviral for a range of respiratory viral infections.